RU2001108716A - METHOD FOR TREATING PERSONS SUFFERING FROM SEPSIS - Google Patents

METHOD FOR TREATING PERSONS SUFFERING FROM SEPSIS

Info

Publication number
RU2001108716A
RU2001108716A RU2001108716/14A RU2001108716A RU2001108716A RU 2001108716 A RU2001108716 A RU 2001108716A RU 2001108716/14 A RU2001108716/14 A RU 2001108716/14A RU 2001108716 A RU2001108716 A RU 2001108716A RU 2001108716 A RU2001108716 A RU 2001108716A
Authority
RU
Russia
Prior art keywords
necrosis factor
tumor necrosis
sepsis
persons suffering
administered
Prior art date
Application number
RU2001108716/14A
Other languages
Russian (ru)
Other versions
RU2197990C2 (en
Inventor
Розвита ШТЕНЦЕЛЬ
Мартин КАУЛЬ
Лотар ДАУМ
Йоахим КЕМПЕНИ
Криста РААБ
Зибилле ШЭФЕР
Original Assignee
Кнолль Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кнолль Акциенгезельшафт filed Critical Кнолль Акциенгезельшафт
Application granted granted Critical
Publication of RU2197990C2 publication Critical patent/RU2197990C2/en
Publication of RU2001108716A publication Critical patent/RU2001108716A/en

Links

Claims (4)

1. Способ лечения лиц, страдающих от сепсиса, путем введения антагониста фактора некроза опухоли, отличающийся тем, что введение осуществляют при уровне интерлейкина-6 в сыворотке, равном больше 1000 пг/мл.1. A method of treating persons suffering from sepsis by administering a tumor necrosis factor antagonist, characterized in that the administration is carried out at a serum interleukin-6 level of more than 1000 pg / ml. 2. Способ по п.1, отличающийся тем, что в качестве антагониста фактора некроза опухоли вводят рецептор фактора некроза опухоли или его растворимый фрагмент.2. The method according to claim 1, characterized in that as a tumor necrosis factor antagonist, a tumor necrosis factor receptor receptor or a soluble fragment thereof is administered. 3. Способ по п.1, отличающийся тем, что в качестве антагониста фактора некроза опухоли вводят моноклональное антитело против фактора некроза опухоли.3. The method according to claim 1, characterized in that as a tumor necrosis factor antagonist, a monoclonal antibody against tumor necrosis factor is administered. 4. Способ по п.3, отличающийся тем, что в качестве моноклонального антитела против фактора некроза опухоли вводят гуманизированное или человеческое антитело против фактора некроза опухоли.4. The method according to claim 3, characterized in that as a monoclonal antibody against tumor necrosis factor, a humanized or human antibody against tumor necrosis factor is administered.
RU2001108716/14A 1994-02-07 1995-01-27 Method for treating sepsis-suffering patients RU2197990C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DEP4403669.8 1994-02-07
DE4403669 1994-02-07
DEP4409513.9 1994-03-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU96118134/14A Division RU96118134A (en) 1994-02-07 1995-01-27 APPLICATION OF ANTIBODIES AGAINST THE TUMOR NECROSIS FACTOR AS A MEDICINE FOR THE TREATMENT OF DISEASES CONNECTED WITH AN INCREASED INTERLEUKIN-6 IN SERUM

Publications (2)

Publication Number Publication Date
RU2197990C2 RU2197990C2 (en) 2003-02-10
RU2001108716A true RU2001108716A (en) 2004-04-20

Family

ID=6509608

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001108716/14A RU2197990C2 (en) 1994-02-07 1995-01-27 Method for treating sepsis-suffering patients

Country Status (5)

Country Link
KR (1) KR100414505B1 (en)
DE (2) DE4409513C1 (en)
RU (1) RU2197990C2 (en)
UA (1) UA46731C2 (en)
ZA (1) ZA95956B (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3631229A1 (en) * 1986-09-13 1988-03-24 Basf Ag MONOCLONAL ANTIBODIES AGAINST HUMAN TUMORNESCROSE FACTOR (TNF) AND THEIR USE
AU648777B2 (en) * 1989-12-04 1994-05-05 Schering Corporation Method of treating septic shock

Similar Documents

Publication Publication Date Title
EP0783893B1 (en) Inhibition of abnormal growth of synovial cells using il-6 antagonist as active ingredient
CA2261630C (en) Anti-tnf antibodies and methotrexate in the treatment of autoimmune disease
US8017121B2 (en) Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
HUT76875A (en) Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels
US20020176858A1 (en) Monoclonal antibodies to TGF-BETA
CA2089229A1 (en) Cd40cr receptor and ligands therefor
NO20051048L (en) Therapeutic human anti-IL-1R1 monoclonal antibody
HUP9802483A3 (en) Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies, as therapeutic agents for the treatment of immunological disease
DE69724451D1 (en) COMBINATION THERAPY WITH A TNF-BINDING PROTEIN FOR TREATING DISEASES CAUSED BY TNF
CA2290021A1 (en) Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy
WO1995019570B1 (en) Antagonists to insulin receptor tyrosine kinase inhibitor
Hansen et al. Influence of interleukin‐6 (IL‐6) autoantibodies on IL‐6 binding to cellular receptors
RU2004137823A (en) THERAPEUTIC AGAINST HYPERCALCEMIC CRISIS
CA2364026A1 (en) Anti-tnf.alpha. antibodies in therapy of asthma
BG103416A (en) Soluble lymphotoxin-beta receptors, antilymphotosoluble lymphotoxin- receptors, antilymphotoxin receptor antibodies and antilymphotoxin ligand antixin receptor antibodies and antilymphotoxin ligandbodies as therapeutical forms for the treatment of antibodies as therapeutical forms for the treatment of immunological diseases immunological diseases
EP0525570A2 (en) Anti-idiotypic antibodies that mimic TNF
CA2002144A1 (en) Method of preventing or reducing eosinophilia
RU2001108716A (en) METHOD FOR TREATING PERSONS SUFFERING FROM SEPSIS
FI922551A (en) FOERFARANDE FOER SKOETSEL AV SEPTISK CHOCK.
Marusić-Galesić et al. Cellular immune response to the antigen administered as an immune complex.
Koyama et al. Effect of chemical modification of antigen on characteristics of immune complexes and their glomerular localization in the murine renal tissues.
DE69630761D1 (en) METHOD FOR REDUCING THE RENAL ENTRANCE OF ANTIBODY FRAGMENTS
RU2000112873A (en) APPLICATION OF ANTAGONISTS OF THE TUMOR NECROSIS FACTOR FOR THE PRODUCTION OF MEDICINES FOR THE TREATMENT OF SEPTIC DISEASES
RU2197990C2 (en) Method for treating sepsis-suffering patients
AU732764B2 (en) Rheumatoid arthritis remedy containing IL-6 antagonist as effective component